Ланреотид в лечении больных c диссеминированными высокодифференцированными нейроэндокринными опухолями: опыт применения при неудовлетворительной переносимости октреотида

Abstract

Somatostatin analogs plays a key role in the treatment of disseminated well-differentiated functioning and nonfunctioning neuroendocrine tumors (NET). Its ingibit hormonal activity of NET by binding to somatostatin receptors, have antiproliferative effect, increase the median time to progression. Approximately 10% of patients have significant side-effects when used octreotide. Octreotide and lanreotide differ in structure. Intolerance to one drug, it may be assigned to another.